{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T01:40:15Z","timestamp":1759196415842,"version":"3.44.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in older adults, with its prevalence rising globally. This review aims to explore the potential of Efdamrofusp alfa (EA), a novel bispecific decoy receptor fusion protein targeting both VEGF and complement pathways, in treating neovascular AMD (nAMD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A comprehensive literature search was conducted across PubMed, Cochrane and Embase till March 2025 to find articles evaluating the efficacy of EA in the treatment of neovascular AMD. Observations from early pre-clinical studies and clinical trials were analyzed to determine the efficacy and safety of EA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of five preclinical and clinical studies were included, encompassing 66 animal subjects and 880 human participants. Efdamrofusp alfa (IBI302) neutralizes both C3b\/C4b and VEGF, demonstrating anti-angiogenic effects in preclinical models. Clinical trials examined intravitreal doses ranging from 0.05\u00a0mg to 4.00\u00a0mg. EA showed efficacy in reducing central retinal thickness and improving visual acuity, with a safety profile comparable to existing anti-VEGF treatments. Treatment-emergent adverse events (TEAEs) included conjunctival hemorrhage, ocular hypertension, and keratitis, which were similar to those observed with other intravitreal anti-VEGF drugs. The drug demonstrated noninferiority to aflibercept in improving best-corrected visual acuity (BCVA) and significantly reduced central subfield thickness.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Efdamrofusp alfa shows promise as a novel treatment for nAMD, potentially offering improved efficacy over current anti-VEGF therapies. Nonetheless, further large-scale randomized clinical trials are essential to confirm its efficacy and safety in broader populations. The dual-inhibition strategy provides a new avenue for personalized AMD treatment, particularly for patients unresponsive to monotherapies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40942-025-00685-2","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:23:47Z","timestamp":1759173827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efdamrofusp alfa: an insight into the novel drug and its use in age-related macular degeneration"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4273-0827","authenticated-orcid":false,"given":"Shree","family":"Rath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arwa Amer","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arashdeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arghadip","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayed Mansoor","family":"Sediqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najia Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisha","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safwan Masaud","family":"Mian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"11","key":"685_CR1","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","volume":"102","author":"FL Ferris","year":"1984","unstructured":"Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102(11):1640\u20132.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"685_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1159\/000517520","volume":"244","author":"R Flores","year":"2021","unstructured":"Flores R, Carneiro \u00c2, Vieira M, Tenreiro S, Seabra MC. Age-related macular degeneration: pathophysiology, management, and future perspectives. Ophthalmologica. 2021;244(6):495\u2013511.","journal-title":"Ophthalmologica"},{"issue":"2","key":"685_CR3","first-page":"74","volume":"59","author":"A Gheorghe","year":"2015","unstructured":"Gheorghe A, Mahdi L, Musat O. Age-related macular degeneration. Roman J Ophthalmol. 2015;59(2):74\u20137.","journal-title":"Roman J Ophthalmol."},{"issue":"1","key":"685_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0039-6257(99)00072-7","volume":"44","author":"A Abdelsalam","year":"1999","unstructured":"Abdelsalam A, Del Priore L, Zarbin MA. Drusen in age-related macular degeneration. Surv Ophthalmol. 1999;44(1):1\u201329.","journal-title":"Surv Ophthalmol"},{"issue":"10","key":"685_CR5","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1001\/archopht.125.10.1357","volume":"125","author":"ZF Bashshur","year":"2007","unstructured":"Bashshur ZF, Schakal A, Hamam RN, Haibi CPE, Jaafar RF, Noureddin BN. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol. 2007;125(10):1357\u201361.","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"685_CR6","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1016\/j.ophtha.2019.11.025","volume":"127","author":"JW Miller","year":"2020","unstructured":"Miller JW. Comparison of age-related macular degeneration treatments trials 2: introducing comparative effectiveness research. Ophthalmology. 2020;127(4):S133\u20134.","journal-title":"Ophthalmology"},{"issue":"6","key":"685_CR7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.ophtha.2018.09.015","volume":"126","author":"RH Guymer","year":"2019","unstructured":"Guymer RH, Wu Z, Hodgson LAB, Caruso E, Brassington KH, Tindill N, et al. Subthreshold nanosecond laser intervention in age-related macular degeneration. Ophthalmology. 2019;126(6):829\u201338.","journal-title":"Ophthalmology"},{"issue":"2","key":"685_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000337347","volume":"228","author":"ID Ladas","year":"2012","unstructured":"Ladas ID, Chatziralli IP, Kotsolis AI, Douvali M, Georgalas I, Theodossiadis PG, et al. Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration. Ophthalmologica. 2012;228(2):93\u2013101.","journal-title":"Ophthalmologica"},{"key":"685_CR9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.exer.2016.02.004","volume":"145","author":"X Ren","year":"2016","unstructured":"Ren X, Li J, Xu X, Wang C, Cheng Y. IBI302, a promising candidate for AMD treatment, targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys. Exp Eye Res. 2016;145:352\u20138.","journal-title":"Exp Eye Res"},{"issue":"647","key":"685_CR10","doi-asserted-by":"publisher","first-page":"eabj2177","DOI":"10.1126\/scitranslmed.abj2177","volume":"14","author":"S Yang","year":"2022","unstructured":"Yang S, Li T, Jia H, Gao M, Li Y, Wan X, et al. Targeting C3b\/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy. Sci Transl Med. 2022;14(647):eabj2177.","journal-title":"Sci Transl Med."},{"issue":"12","key":"685_CR11","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/1947601911423031","volume":"2","author":"M Shibuya","year":"2011","unstructured":"Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis. Genes Cancer. 2011;2(12):1097\u2013105. https:\/\/doi.org\/10.1177\/1947601911423031.","journal-title":"Genes Cancer"},{"key":"685_CR12","first-page":"281","volume-title":"Advances in cancer research","author":"M Shibuya","year":"1995","unstructured":"Shibuya M. Role of vegf-flt receptor system in normal and tumor angiogenesis. In: Vande Woude GF, Klein G, editors. Advances in cancer research, vol. 67. Academic Press; 1995. p. 281\u2013316."},{"issue":"8","key":"685_CR13","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.4049\/jimmunol.1203487","volume":"190","author":"D Ricklin","year":"2013","unstructured":"Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol Baltim Md 1950. 2013;190(8):3831\u20138. https:\/\/doi.org\/10.4049\/jimmunol.1203487.","journal-title":"J Immunol Baltim Md 1950."},{"issue":"4","key":"685_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/antib9040067","volume":"9","author":"MM Markiewski","year":"2020","unstructured":"Markiewski MM, Daugherity E, Reese B, Karbowniczek M. The role of complement in angiogenesis. Antibodies. 2020;9(4):67. https:\/\/doi.org\/10.3390\/antib9040067.","journal-title":"Antibodies"},{"issue":"7","key":"685_CR15","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1073\/pnas.0408835103","volume":"103","author":"M Nozaki","year":"2006","unstructured":"Nozaki M, Raisler BJ, Sakurai E, et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A. 2006;103(7):2328\u201333. https:\/\/doi.org\/10.1073\/pnas.0408835103.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"685_CR16","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1001\/archopht.1990.01070120090035","volume":"108","author":"SB Bressler","year":"1990","unstructured":"Bressler SB, Maguire MG, Bressler NM, Fine SL. Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group. Arch Ophthalmol Chic Ill 1960. 1990;108(10):1442\u20137. https:\/\/doi.org\/10.1001\/archopht.1990.01070120090035.","journal-title":"Arch Ophthalmol Chic Ill 1960."},{"issue":"5720","key":"685_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1126\/science.1109557","volume":"308","author":"RJ Klein","year":"2005","unstructured":"Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385\u20139. https:\/\/doi.org\/10.1126\/science.1109557.","journal-title":"Science"},{"issue":"7","key":"685_CR18","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1096\/fj.14-251041","volume":"28","author":"JH Sweigard","year":"2014","unstructured":"Sweigard JH, Yanai R, Gaissert P, et al. The alternative complement pathway regulates pathological angiogenesis in the retina. FASEB J. 2014;28(7):3171\u201382. https:\/\/doi.org\/10.1096\/fj.14-251041.","journal-title":"FASEB J"},{"key":"685_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2022.11.016","volume":"248","author":"H Jia","year":"2023","unstructured":"Jia H, Li T, Sun J, et al. A novel bispecific fusion protein targeting C3b\/C4b and VEGF in patients With nAMD: a randomized, open-label, Phase 1b study. Am J Ophthalmol. 2023;248:8\u201315. https:\/\/doi.org\/10.1016\/j.ajo.2022.11.016.","journal-title":"Am J Ophthalmol"},{"key":"685_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.08.014","author":"J Sun","year":"2024","unstructured":"Sun J, Song Y, Gong Y, et al. Efficacy and safety of efdamrofusp alfa versus aflibercept in participants with neovascular age-related macular degeneration: a randomized, double-masked, active-controlled, non-inferiority, phase 2 trial. Ophthalmol Retina. 2024. https:\/\/doi.org\/10.1016\/j.oret.2024.08.014.","journal-title":"Ophthalmol Retina."},{"key":"685_CR21","unstructured":"A Phase 3, Randomized, Double-masked, Active-Controlled Study to Evaluate the Efficacy and Safety of Intravitreal IBI302(Efdamrofusp Alfa) in Subjects With Neovascular Age-Related Macular Degeneration. Published online July 25, 2023. Accessed August 15, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05972473."},{"issue":"12","key":"685_CR22","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration [published correction appears in Ophthalmology. Ophthalmology. 2012;119(12):2537\u201348. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006.","journal-title":"Ophthalmology"},{"key":"685_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","volume":"65","author":"H Mehta","year":"2018","unstructured":"Mehta H, Tufail A, Daien V, et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res. 2018;65:127\u201346. https:\/\/doi.org\/10.1016\/j.preteyeres.2017.12.002.","journal-title":"Prog Retin Eye Res"},{"issue":"20","key":"685_CR24","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897\u2013908. https:\/\/doi.org\/10.1056\/NEJMoa1102673.","journal-title":"N Engl J Med"},{"issue":"8","key":"685_CR25","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","volume":"123","author":"MG Maguire","year":"2016","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire MG, Martin DF, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(8):1751\u201361. https:\/\/doi.org\/10.1016\/j.ophtha.2016.03.045.","journal-title":"Ophthalmology"},{"issue":"11","key":"685_CR26","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2013.03.046.","journal-title":"Ophthalmology"},{"issue":"1","key":"685_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","volume":"4","author":"TA Ciulla","year":"2020","unstructured":"Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 Eyes. Ophthalmol Retina. 2020;4(1):19\u201330. https:\/\/doi.org\/10.1016\/j.oret.2019.05.017.","journal-title":"Ophthalmol Retina"},{"key":"685_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100906","volume":"82","author":"PS Mettu","year":"2021","unstructured":"Mettu PS, Allingham MJ, Cousins SW. Incomplete response to Anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res. 2021;82: 100906. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100906.","journal-title":"Prog Retin Eye Res"},{"key":"685_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.preteyeres.2015.06.002","volume":"49","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015;49:67\u201381. https:\/\/doi.org\/10.1016\/j.preteyeres.2015.06.002.","journal-title":"Prog Retin Eye Res"},{"key":"685_CR30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013;27:787\u201394.","journal-title":"Eye (Lond)"},{"issue":"1","key":"685_CR31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/sj.eye.6702938","volume":"23","author":"SJ Bakri","year":"2009","unstructured":"Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond). 2009;23(1):181\u20135. https:\/\/doi.org\/10.1038\/sj.eye.6702938.","journal-title":"Eye (Lond)"},{"issue":"9","key":"685_CR32","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/IJG.0b013e31819c4893","volume":"18","author":"M Gismondi","year":"2009","unstructured":"Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma. 2009;18(9):658\u201361. https:\/\/doi.org\/10.1097\/IJG.0b013e31819c4893.","journal-title":"J Glaucoma"},{"issue":"3","key":"685_CR33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3928\/15428877-20090430-12","volume":"40","author":"MY Kahook","year":"2009","unstructured":"Kahook MY, Kimura AE, Wong LJ, Ammar DA, Maycotte MA, Mandava N. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging. 2009;40(3):293\u20135. https:\/\/doi.org\/10.3928\/15428877-20090430-12.","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"2","key":"685_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ophtha.2011.08.011","volume":"119","author":"QV Hoang","year":"2012","unstructured":"Hoang QV, Mendonca LS, Della Torre KE, Jung JJ, Tsuang AJ, Freund KB. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology. 2012;119(2):321\u20136. https:\/\/doi.org\/10.1016\/j.ophtha.2011.08.011.","journal-title":"Ophthalmology"},{"issue":"8","key":"685_CR35","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1136\/bjo.2010.180729","volume":"95","author":"TJ Good","year":"2011","unstructured":"Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011;95(8):1111\u20134. https:\/\/doi.org\/10.1136\/bjo.2010.180729.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"685_CR36","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1097\/IAE.0b013e3181cd47ed","volume":"30","author":"D Mezad-Koursh","year":"2010","unstructured":"Mezad-Koursh D, Goldstein M, Heilwail G, Zayit-Soudry S, Loewenstein A, Barak A. Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor. Retina. 2010;30(7):1051\u20137. https:\/\/doi.org\/10.1097\/IAE.0b013e3181cd47ed.","journal-title":"Retina"},{"issue":"10","key":"685_CR37","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.ophtha.2011.02.034","volume":"118","author":"CP Shah","year":"2011","unstructured":"Shah CP, Garg SJ, Vander JF, et al. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology. 2011;118(10):2028\u201334. https:\/\/doi.org\/10.1016\/j.ophtha.2011.02.034.","journal-title":"Ophthalmology"},{"key":"685_CR38","unstructured":"https:\/\/www.prnewswire.com\/news-releases\/innovent-announces-primary-endpoint-met-in-the-second-phase-2-clinical-trial-of-ibi302-anti-vegfcomplement-in-treating-neovascular-age-related-macular-degeneration-namd-302091578.html cited 15th September,2024"},{"key":"685_CR39","unstructured":"Juan et al. \u201cLimited macular translocation\u201d eye2001146"},{"key":"685_CR40","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.2147\/dddt.s427416","volume":"17","author":"G Panos","year":"2023","unstructured":"Panos G, Lakshmanan A, Dadoukis P, Ripa M, Motta L, Amoaku W. Faricimab: transforming the future of macular diseases treatment - a comprehensive review of clinical studies. Drug Des Dev Ther. 2023;17:2861\u201373. https:\/\/doi.org\/10.2147\/dddt.s427416.","journal-title":"Drug Des Dev Ther"},{"key":"685_CR41","doi-asserted-by":"publisher","DOI":"10.1177\/25158414211027708","author":"PR Chandrasekaran","year":"2021","unstructured":"Chandrasekaran PR, Madanagopalan VG. KSI-301: antibody biopolymer conjugate in retinal disorders. Ther Adv Ophthalmol. 2021. https:\/\/doi.org\/10.1177\/25158414211027708.","journal-title":"Ther Adv Ophthalmol"},{"key":"685_CR42","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/s0140-6736(24)00310-6","volume":"403","author":"PA Campochiaro","year":"2024","unstructured":"Campochiaro PA, Avery R, Brown DM, Heier JS, Ho AC, Huddleston SM, et al. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study. The Lancet. 2024;403:1563\u201373. https:\/\/doi.org\/10.1016\/s0140-6736(24)00310-6.","journal-title":"The Lancet"},{"key":"685_CR43","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ophtha.2023.02.001","volume":"130","author":"TL Jackson","year":"2023","unstructured":"Jackson TL, Slakter J, Buyse M, Wang K, Dugel PU, Wykoff CC, et al. A randomized controlled trial of OPT-302, a VEGF-C\/D inhibitor for neovascular age-related macular degeneration. Ophthalmology. 2023;130:588\u201397. https:\/\/doi.org\/10.1016\/j.ophtha.2023.02.001.","journal-title":"Ophthalmology"},{"key":"685_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13010100","author":"N Anton","year":"2022","unstructured":"Anton N, Doroftei B, Curteanu S, Cat\u00e3lin L, Ilie OD, T\u00e2rcoveanu F, et al. Comprehensive review on the use of artificial intelligence in ophthalmology and future research directions. Diagnostics (Basel). 2022. https:\/\/doi.org\/10.3390\/diagnostics13010100.","journal-title":"Diagnostics (Basel)."},{"issue":"1","key":"685_CR45","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12967-023-03937-7","volume":"21","author":"LM Khachigian","year":"2023","unstructured":"Khachigian LM, Liew G, Teo KYC, Wong TY, Mitchell P. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. J Transl Med. 2023;21(1):133.","journal-title":"J Transl Med"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00685-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00685-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00685-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T01:03:14Z","timestamp":1759194194000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-025-00685-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["685"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00685-2","relation":{},"ISSN":["2056-9920"],"issn-type":[{"type":"electronic","value":"2056-9920"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}